Navigation Links
Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
Date:8/27/2012

August 27, 2012 -- In one of the most comprehensive peer-reviewed discussions on cancer vaccines and immunotherapeutics, a Special Focus in the journal Human Vaccines & Immunotherapeutics provides a critical view on cancer vaccines and a discussion on best approaches for the future. From firsthand accounts of principal investigators involved in numerous failed cancer vaccine programs, including Oncophage and MVAX, to commentary from world experts in cancer vaccine development, authors in the Special Focus recount the mistakes of the past and provide an critical lens into the future of cancer vaccines with a potential for success.

Of special consideration is the technological advancement in Second Generation DNA sequencing technology that has resulted in the vast amount of genetic data of tumor cells gathered over the past few years. According to authors in the Special Focus, these data confirm that the degree of antigenic heterogeneity of tumor cells has been greatly underestimated. Tumors, once thought to be made of homogeneous collections of cells, are actually comprised of cells that carry an extreme diversity of antigens, the molecular signatures that are responsible for triggering immune response against cancer. This influences the important area of Antigen Discovery, a major criteria of vaccine formulation.

"Due in large part to genomic sequencing data, it has become quite clear that cancer is a heterogeneous disease and thus cannot be treated by homogeneous therapies. Many past cancer vaccine programs were based on the false premise of tumor homogeneity," said Michael G. Hanna, Jr., Ph.D., guest editor and contributor in the Special Focus series. "With all that we have learned at both the tumor genomic and immunotherapeutic levels, it is essential to reevaluate the antigen discovery process. The use of the patient's own tumor is the purest means to obtain a robust tumor-specific immune response."

The promise of triggering the immune system to engage a perpetual defense against resilient and hard-to-find cancer cells continues to prompt research. There are approximately 150 therapeutic cancer vaccines in clinical development. Despite past failures of cancer vaccines, new science continues to validate and support cancer vaccine technologies. In this Special Focus, authors outline weak clinical trial design, manufacturing issues relating to short shelf life and sterility of product, and failure to identify proper dose, schedule and route of administration among the key reasons why more cancer vaccines are not on the market today.

Ronald Ellis, Ph.D., Editor-in-Chief of Human Vaccines & Immunotherapeutics, said: "Despite the accumulation of sound science that continues to support cancer immunotherapy approaches, there are serious gaps in the cancer vaccine R&D pipeline. Some new cancer vaccine technologies that apply the lessons learned from many years of trials and tribulations are in late stages of clinical development and could lead to realization of the promise of cancer immunotherapy."

The Special Focus appearing in the August 2012 issue includes an introduction, five original papers and a guest editorial. Selected experts include: David Berd, M.D. (DB Consultants; Wyncote, PA, USA), Mike Cusnir, M.D. (Mount Sinai Comprehensive Cancer Center; Miami Beach, FL, USA), Isaiah Fidler, Ph.D. (University of Texas MD Anderson Cancer Center, Houston, TX, USA), Michael G. Hanna, Jr., Ph.D. (Vaccinogen Inc, Frederick, MD, USA), and Dirk Reitsma, M.D., and Austin Combest, Pharm.D. (PPD, Wilmington, NC, USA). Guest Editors include: Alex Kudrin, M.D., Ph.D. (Consultant in Pharmaceuticals Medicine, London, UK) and Michael G. Hanna, Jr., Ph.D. (Vaccinogen Inc, Frederick, MD, USA). This is the first of two special sections in the Cancer Commentary Series, the second will appear in the September 2012 issue.


'/>"/>

Contact: Betsy Granger
hv@landesbioscience.com
Human Vaccines & Immunotherapeutics, Landes Bioscience
Source:Eurekalert

Related medicine news :

1. Obese and overweight women face increased risk of recurrence of most common type of breast cancer
2. Radiation for Childhood Cancer Might Raise Diabetes Risk
3. Missing Follow-Up Colonoscopies Could Raise Colon Cancer Risk
4. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
5. Circadian clock research may enable designer plants, and cancer and diabetes treatments
6. Learning 1 of cancers tricks
7. Study helps pancreatic cancer patients make hard choices
8. PSA Testing Linked to Improved Prostate Cancer Survival
9. New insights into why humans are more susceptible to cancer and other diseases
10. Cancer survival in Germany after the fall of the Iron Curtain
11. Vanderbilt-led study reveals racial disparities in prostate cancer care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology: